ImpriMed, founded in 2017 in Silicon Valley, is a leading precision medicine startup revolutionizing cancer treatment with artificial intelligence. The company's pioneering drug response prediction technology helps reduce costs, accelerate treatment, enhance efficacy, and improve the quality of life for patients. To date, the company's technology has been deployed across more than 40 U.S. states, and 15,000+ canine and feline blood cancer tests have been performed as of 2023. ImpriMed is now poised to extend its groundbreaking AI-driven approach to human healthcare, redefining the future of oncology treatment with personalized, effective solutions.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 12/19/23 | $23,000,000 | Series A |
Byucksan HRZ Han River Partners Ignite Innovation KDB Silicon Valley Murex Partners Samyang Chemical Group SBVA  SK Telecom Ventures | undisclosed |
